A share price of Pacific Biosciences of California Inc [PACB] is currently trading at $1.80, up 1.69%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The PACB shares have gain 12.85% over the last week, with a monthly amount glided 4.65%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Pacific Biosciences of California Inc [NASDAQ: PACB] stock has seen the most recent analyst activity on November 11, 2024, when UBS downgraded its rating to a Neutral. On April 22, 2024, downgrade downgraded it’s rating to Neutral. Goldman downgraded its rating to a Neutral and decreased its price target to $2.50 on April 18, 2024. Stephens initiated its recommendation with a Overweight and recommended $11 as its price target on December 14, 2023. In a note dated December 13, 2023, Wolfe Research initiated an Peer Perform rating.
Pacific Biosciences of California Inc experienced fluctuations in its stock price throughout the past year between $1.16 and $10.65. Currently, Wall Street analysts expect the stock to reach $3 within the next 12 months. Pacific Biosciences of California Inc [NASDAQ: PACB] shares were valued at $1.80 at the most recent close of the market. An investor can expect a potential return of 66.67% based on the average PACB price forecast.
Analyzing the PACB fundamentals
Trailing Twelve Months sales for Pacific Biosciences of California Inc [NASDAQ:PACB] were 173.15M which represents -28.23% decline. Gross Profit Margin for this corporation currently stands at 0.18% with Operating Profit Margin at -2.15%, Pretax Profit Margin comes in at -2.28%, and Net Profit Margin reading is -2.28%. To continue investigating profitability, this company’s Return on Assets is posted at -0.27, Equity is -0.69 and Total Capital is -0.27. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of2.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.7000 points at the first support level, and at 1.6000 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.8950, and for the 2nd resistance point, it is at 1.9900.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Pacific Biosciences of California Inc [NASDAQ:PACB] is 9.74. As well, the Quick Ratio is 8.64, while the Cash Ratio is 1.3. Considering the valuation of this stock, the price to sales ratio is 2.90, the price to book ratio is 1.09.
Transactions by insiders
Recent insider trading involved Kim Susan G.,, that happened on Sep 30 ’24 when 19782.0 shares were sold. Officer, SUSAN KIM completed a deal on Sep 30 ’24 to buy 19782.0 shares. Meanwhile, HENRY CHRISTIAN O sold 98907.0 shares on Sep 16 ’24.
